Gordon assists pharmaceutical manufacturers, life sciences companies, and healthcare organizations to navigate oncology care pathways—with a focus on making cancer treatment accessible and affordable for diverse patient populations, including union health plans and working families.
Experience
With over 20 years in oncology strategy and clinical pathways, he works across the healthcare ecosystem to ensure cancer therapies reach patients effectively. His experience spans pharmaceutical companies, payers, providers, and diverse delivery systems—including Taft-Hartley trust funds and self-insured labor health plans that serve working people.
He also founded and led healthcare technology companies, including a HIPAA compliance organization, which gives him a well-rounded perspective on the operational and regulatory challenges facing healthcare stakeholders.
Services
Clinical Pathways & Access Strategy
He helps navigate therapy placement across major vendors and cancer centers, focusing on decision criteria that balance clinical excellence with the financial realities facing union health funds and diverse patient populations.
Market Access & Value-Based Intelligence
He works with stakeholders to understand payer perspectives, including those of multiemployer trust funds, and decode emerging reimbursement frameworks like CMS’s Enhancing Oncology Model (EOM).
Practice Economics for Diverse Care Settings
He quantifies provider impact and develop compelling value narratives for community cancer centers, safety-net hospitals, and the full range of settings where patients receive care.
Approach
Having collaborated with major pathway developers and large oncology provider networks, he understands what drives results across different populations and care settings. He delivers practical, actionable strategies that account for real-world complexity—from market access planning to comprehensive stakeholder engagement—always keeping patient access and affordability in focus.